Gene editing to treat transthyretin amyloidosis with cardiomyopathy - PACE-CME

Gene editing to treat transthyretin amyloidosis with cardiomyopathy

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Long-term efficacy and safety of intravenous iron in HF
Long-term efficacy and safety of intravenous iron in HF
AHA 2022
Long-term efficacy and safety of intravenous iron in HF
Low-dose statin lowers LDL-c more than dietary supplements
Low-dose statin lowers LDL-c more than dietary supplements
AHA 2022
Low-dose statin lowers LDL-c more than dietary supplements
- Luke J. Laffin, MD
Improved outcomes with rapid uptitration of HF medication after acute HF
Improved outcomes with rapid uptitration of HF medication after acute HF
AHA 2022
Improved outcomes with rapid uptitration of HF medication after acute HF
- Prof. Alexandre Mebazaa, MD, PhD
Composite endpoint of CV death or kidney disease worsening reduced by SGLT2i in CKD
Composite endpoint of CV death or kidney disease worsening reduced by SGLT2i in CKD
AHA 2022
Composite endpoint of CV death or kidney disease worsening reduced by SGLT2i in CKD
- David Preiss, PhD